News in Brief
Boehringer’s success gives EU another Humira biosimilar
The EC nod makes Cyltezo the first biosimilar to be successful in Europe for Boehringer Ingelheim, and the forth version of AbbVie’s bestselling biologic Humira to be approved following Amgen’s Amgevita and duplicate product Solymbic in March, and Samsung Bioepis' Imraldi in August.
“Cyltezo is the first biosimilar from Boehringer Ingelheim approved in Europe, and marks a significant step forward for us in offering effective, and more affordable treatment options for patients with chronic inflammatory diseases,” said Ivan Blanarik, head of Therapeutic Area Biosimilars at the German firm.
“We believe biosimilars will be a key contributor to the future sustainability of healthcare systems around the world.”
The news comes three months after Boehringer Ingelheim received approval for the biosimilar in the US.
